J. Mould

639 total citations
27 papers, 445 citations indexed

About

J. Mould is a scholar working on Obstetrics and Gynecology, Surgery and Reproductive Medicine. According to data from OpenAlex, J. Mould has authored 27 papers receiving a total of 445 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Obstetrics and Gynecology, 10 papers in Surgery and 10 papers in Reproductive Medicine. Recurrent topics in J. Mould's work include Ovarian cancer diagnosis and treatment (10 papers), Endometrial and Cervical Cancer Treatments (9 papers) and Chemotherapy-induced organ toxicity mitigation (6 papers). J. Mould is often cited by papers focused on Ovarian cancer diagnosis and treatment (10 papers), Endometrial and Cervical Cancer Treatments (9 papers) and Chemotherapy-induced organ toxicity mitigation (6 papers). J. Mould collaborates with scholars based in United Kingdom, Australia and South Africa. J. Mould's co-authors include G. Blackledge, D. Spooner, T. Latief, C. A. Meanwell, A.D. Chetiyawardana, E. J. Buxton, David Luesley, J. A. Jordan, Ciarán Woodman and Frank Lawton and has published in prestigious journals such as JNCI Journal of the National Cancer Institute, Radiology and Annals of Oncology.

In The Last Decade

J. Mould

26 papers receiving 418 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Mould United Kingdom	14	217	183	168	118	102	27	445
Wayne A. Christopherson United States	13	205 0.9×	118 0.6×	203 1.2×	90 0.8×	66 0.6×	24	474
Piver Ms United States	12	131 0.6×	115 0.6×	222 1.3×	130 1.1×	52 0.5×	43	440
Joan E. Woodward United States	11	230 1.1×	112 0.6×	188 1.1×	112 0.9×	72 0.7×	12	454
J.Max Austin United States	13	403 1.9×	304 1.7×	268 1.6×	176 1.5×	212 2.1×	24	747
Jacob M. Estes United States	12	111 0.5×	202 1.1×	205 1.2×	144 1.2×	57 0.6×	36	516
Shashikant B. Lele United States	13	322 1.5×	255 1.4×	531 3.2×	118 1.0×	39 0.4×	29	699
D Barnhill United States	9	306 1.4×	173 0.9×	327 1.9×	51 0.4×	113 1.1×	14	494
Decker Dg United States	12	191 0.9×	154 0.8×	375 2.2×	136 1.2×	48 0.5×	22	598
Siobhan M. Kehoe United States	15	387 1.8×	255 1.4×	385 2.3×	138 1.2×	73 0.7×	41	686
William J. Hoskins United States	8	294 1.4×	249 1.4×	300 1.8×	89 0.8×	41 0.4×	8	565

Countries citing papers authored by J. Mould

Since Specialization

Citations

This map shows the geographic impact of J. Mould's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Mould with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Mould more than expected).

Fields of papers citing papers by J. Mould

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Mould. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Mould. The network helps show where J. Mould may publish in the future.

Co-authorship network of co-authors of J. Mould

This figure shows the co-authorship network connecting the top 25 collaborators of J. Mould. A scholar is included among the top collaborators of J. Mould based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Mould. J. Mould is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Poole, Christopher, Timothy Perren, Andrea Burton, et al.. (2000). Phase II clinical trials of cisplatin-then-paclitaxel and paclitaxel-then-cisplatin in patients with previously untreated advanced epithelial ovarian cancer. Annals of Oncology. 11(12). 1603–1608. 2 indexed citations

Redman, C. W. E., J. Mould, Jane Warwick, et al.. (1993). The west Midlands epithelial ovarian cancer adjuvant therapy trial. Clinical Oncology. 5(1). 1–5. 14 indexed citations

Adab, F. & J. Mould. (1992). Carboplatin and retroperitoneal fibrosis. Clinical Oncology. 4(5). 327–328. 4 indexed citations

Souberbielle, B.E., et al.. (1991). Glycoprotein patterns in normal and malignant cervical tissue. Cancer Letters. 58(3). 247–254. 5 indexed citations

Blackledge, G., E. J. Buxton, J. Mould, et al.. (1990). Phase II studies of ifosfamide alone and in combination in cancer of the cervix. Cancer Chemotherapy and Pharmacology. 26(S1). S12–S16. 10 indexed citations

Lawton, Frank, C. A. Meanwell, J. Mould, & G. Blackledge. (1990). A five-drug alternating chemotherapy regimen for patients with advanced epithelial ovarian cancer. Gynecologic Oncology. 36(1). 19–22. 2 indexed citations

Lawton, F., David Luesley, G. Blackledge, et al.. (1990). A randomized trial comparing whole abdominal radiotherapy with chemotherapy following cisplatinum cytoreduction in epithelial ovarian cancer. West midlands ovarian cancer group trial II. Clinical Oncology. 2(1). 4–9. 32 indexed citations

Barton, Claire, E. J. Buxton, G. Blackledge, J. Mould, & C. A. Meanwell. (1990). A phase II study of ifosfamide in endometrial cancer. Cancer Chemotherapy and Pharmacology. 26(S1). S4–S6. 16 indexed citations

Tobias, Jeffrey, E. J. Buxton, G. Blackledge, et al.. (1990). Neoadjuvant bleomycin, ifosfamide and cisplatin in cervical cancer. Cancer Chemotherapy and Pharmacology. 26(S1). S59–S62. 39 indexed citations

10.

Lawton, Frank, Chris Hilton, J. Mould, Karen K. L. Chan, & G. Blackledge. (1990). Short-duration (three cycles) cisplatin combination chemotherapy with alkylating agent consolidation in advanced epithelial ovarian cancer. Gynecologic Oncology. 40(3). 225–229. 1 indexed citations

11.

Buxton, E. J., C. A. Meanwell, J. Mould, et al.. (1989). Combination Bleomycin, Ifosfamide, and Cisplatin Chemotherapy in Cervical Cancer. JNCI Journal of the National Cancer Institute. 81(5). 359–361. 75 indexed citations

12.

Redman, Charles, Frank Lawton, N Stuart, et al.. (1989). Phase II study of combination 4?-epidoxorubicin and mitomycin C in recurrent epithelial ovarian cancer. Cancer Chemotherapy and Pharmacology. 23(1). 6 indexed citations

13.

Blackledge, G., J. Mould, John Monaghan, et al.. (1989). The role of ifosfamide in cervical cancer.. PubMed. 16(1 Suppl 3). 60–7. 10 indexed citations

14.

Woodman, Ciarán, J. Mould, & J. A. Jordan. (1988). Radiotherapy in the management of vaginal intraepithelial neoplasia after hysterectomy. BJOG An International Journal of Obstetrics & Gynaecology. 95(10). 976–979. 32 indexed citations

15.

Priestman, T.J., et al.. (1988). Randomized Trial Comparing Aminoglutethimide With High-Dose Medroxyprogesterone Acetate in Therapy for Advanced Breast Carcinomau. JNCI Journal of the National Cancer Institute. 80(14). 1147–1151. 29 indexed citations

16.

Buxton, E. J., C. A. Meanwell, J. Mould, et al.. (1988). Phase II Studies of Bleomycin, Ifosfamide and Cis-Platinum in Advanced and Recurrent Cervical Carcinoma. Acta Oncologica. 27(5). 545–549. 13 indexed citations

17.

Lawton, F., et al.. (1987). Phase II study of mitoxantrone in epithelial ovarian cancer.. PubMed. 71(6). 627–9. 33 indexed citations

18.

Meanwell, C. A., et al.. (1987). Recurrent female pelvic cancer: assessment with transrectal ultrasonography.. Radiology. 162(1). 278–281. 14 indexed citations

19.

Meanwell, C. A., J. Mould, G. Blackledge, et al.. (1986). Phase II study of ifosfamide in cervical cancer.. PubMed. 70(6). 727–30. 40 indexed citations

20.

Perren, Timothy, et al.. (1985). Phase II study of vincristine, mitomycin-C and mitoxantrone in advanced breast cancer: a preliminary report of response and toxicity. Investigational New Drugs. 3(2). 173–177. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact